Matribhumi Samachar English
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry Toronto, Ontario and Arlington, Massachusetts–(Newsfile Corp. – March 18, 2026) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the …
Read More »RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light’s drug development platform with Filament’s GMP manufacturing, Health Canada Dealer’s Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light’s operational scale, global brand presence, and real-world microdosing data with Filament’s pharmaceutical R&D capabilities and patented PEX010 …
Read More »Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light’s drug development platform with Filament’s GMP manufacturing, Health Canada Dealer’s Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light’s operational scale, global brand presence, and real-world microdosing data with Filament’s pharmaceutical R&D capabilities and patented PEX010 …
Read More »Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update
Toronto, Ontario–(Newsfile Corp. – March 3, 2026) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and research and development (“R&D“) initiatives designed to expand …
Read More »